Gilead Sciences' (GILD) Remdesivir Granted FDA Orphan Drug Status for Treatment of COVID-19
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $93.07 +0.16%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.2%
Revenue Growth %: +0.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.2%
Revenue Growth %: +0.8%
Join SI Premium – FREE
Gilead Sciences' (NASDAQ: GILD) Remdesivir Granted FDA Orphan Drug Status for Treatment of coronavirus disease 2019 (COVID-19
| Generic Name: | remdesivir |
|---|---|
| Trade Name: | N/A |
| Date Designated: | 03/23/2020 |
| Orphan Designation: | Treatment of coronavirus disease 2019 (COVID-19) |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Marketing Approval Date: | N/A |
| Approved Labeled Indication: | |
| Exclusivity End Date: | N/A |
| Exclusivity Protected Indication*: | |
| Sponsor: | Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 USA The sponsor address listed is the last reported by the sponsor to OOPD. |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Disc Medicine (IRON) PT Raised to $94 at Stifel
- MeiraGTx Holdings (MGTX) Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
- Ensysce Biosciences (ENSC) Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trader TalkRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
